Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The conversation is about the potential of SCUBE3 to regrow a juvenile hairline. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

SCUBE3 is a potential hair loss treatment that people are hopeful about. It may provide a solution without the side effects of finasteride.

SCUBE3 clinical trials for hair loss treatment to start this year. Treatment may involve regular, painless scalp injections to maintain hair growth.

HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.

Human pluripotent stem cells have been used to create hair and skin, potentially offering a new solution for baldness. A user also mentioned starting finasteride but experiencing unexpected hair thinning.

The user Consistent-Gene1334 shared their positive results in regrowing hair by using topical minoxidil and oral finasteride. Other users in the conversation praised the results and discussed the effectiveness of these treatments for diffuse thinning.

Amplifica's progress on Scube3 is unclear, with no recent updates. The conversation also mentions Minoxidil, finasteride, and RU58841 as hair loss treatments.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

The conversation discusses Scube3, a seemingly new and obscure treatment for hair loss, with limited information available and a link to a patient intake form.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

A 42-year-old had 2,100 grafts transplanted to the frontal third of the scalp, using treatments like Dutasteride, oral Minoxidil, ketoconazole shampoo, dermarolling, and PRP. They plan to add RU58841 and have scheduled SMP to improve cosmetic results.

Stem-cell hair transplants could potentially create thousands of grafts from a single donor graft, offering a solution for hair loss with DHT-resistant hair. Companies like Stemson Therapeutics and OrganTech are working on this technology, which may become available in the future, possibly reducing the cost and making it widely accessible.

High cost of studying 3α-Hydroxysteroid dehydrogenase in hair loss led to suggestions of crowdfunding for research. Users discussed using Procyanidin B2/melatonin topical treatment and tracking funds with blockchain.

The user experienced good crown progress in 3 months using finasteride, collagen, vitamins B, C, D, zinc, and dermarolling. They are pleased with the results after a hair transplant on the front and mid scalp.

The user is 2 months post-hair transplant with 6,000 grafts using the DHI method and is using oral finasteride, minoxidil, and vitamins. They are seeking feedback on their progress.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.